exactly. It will trend down the day of the R/S, then pop the next day. The R/S news has been known for quite some time. There would be no need for shorts to hang around after the R/S. Also, some disgruntled ex-longs will jump back in. I say it goes up from there.
Actually, I've seen just the opposite lately. NEWL is in much worse shape than this company. They've done multiple R/S's. Each time, the stock does trend down the day of the R/S, but the very next day it pops. Some say it's the shorts scrambling to cover as the shares become scarce. We'll see if this happens here. Actually, the huge volume maybe hedge funds anticipating this kind of move. They are shaking the trees for some loose fruit.
I've always wondered about this. It's really the insurance companies that have the final say. The AMA certainly has a lot of sway with them, but I'm not seeing a lot of insurance companies cover MWA yet, though they think it's promising. I looked at most of the major ones and there's still mostly a wait-and-see attitude. They are looking for study results. There are some studies that complete starting in 2015. That's when I think you'll see MWA take off.
can't sell that many shares at the volumes we're seeing. These are light volumes. Somebody is shaking the trees trying to get some stop losses to trigger. That's why you're seeing the bounce from .60. I project the stock will hit .50 before all of this is over. Maybe when the compliance letter comes from the NASDAQ. That's when it'll be time to back up the truck if you want in.
No, BSD Medical has no long term debt so BK is unlikely. They will simply sell more shares to fund operations, then reverse split as the dilution causes the stock price to tank. It's rinse and repeat after that.
6 dilutions since 2009. And not will not get delisted for a year at least but will get compliance notice in a few weeks.
The CEO says those RF codes will work for microwave. I have my doubts, especially when you read the BCBSNC position on microwave. They still consider it investigational, but promising. True in a lot of states but not all.
I think there is a poison pill in place though I haven't been able to find it.
bluechiptool, check your Yahoo e-mail for info related to your investment in BSD Medical. If you don't use that account, reply to this message indicating such, and I'll figure out a way to get it to you.
It's curious that it's not going better than it is. $480k in consumable revenues over a 13 week period is $37k per week. Let's say each antenna is $1k and they do one procedure per week. Then that's 37 machines. If they only get $500 per antenna (because of 50% revenue sharing with Terumo), that's 74 machines, tops. Terumo is selling into 100 countries. That's less than 1 per country, not particularly remarkable. This is a market that is taking a long time to develop. The 5% drop in revenue this quarter is troublesome. Hope it's not a sign the low lying fruit has all been picked.
Fair comparison with Apple. It's all in the user interface folks. That's what has made Apple the success story that it is. And the cult following when Jobs was alive. Same here. Al Mann, like Steve Jobs and Elon Musk, has a cult following, and that's what all these valuation models on Seeking Alpha are failing to take into account. Tesla's business model was widely panned because its valuation was way out of line and the shorts were having a field day. Then they showed a profit. The stock ran 4x. It's all in the user interface and the cult following. Think about it.
Ask Bill what cities in the US the FPU program is operating in and how many hospitals. There is no Terumo involved. He should be able to tell you. Then report back to us. This would confirm your theory.
Now let's talk about the recurring revenue stream. Let's say they sell 150 MTX-180's in Europe and the US and that the machines are used to do 2 ablations per week, with each taking 1.5 antennae on average at $1,000 a pop. That's $3,000 per machine per week or $23.4M per year in revenue. Take 2x sales or $46.8M as as the valuation for consumables. This doesn't take into account sales in Asia or S. America or India which will surely come once approvals are in place.
There are 33,982,000 shares diluted, with another 5,457,305 in warrants (exercise price of 2.93) and 4,062,239 in options (exercise price of 2.80), which if fully vested and exercised, bring in a total of $27M.
On a per share basis, that gives us ($155M + $120M + $27M + $47M)/44M = $7.93 per share
A potential suitor will typically pay more than the most recent high peak to get all shareholders to buy-in to avoid costly shareholder litigation. The peak on 11/20/2014 was $7.40. If they pay $7.50 or more, they can avoid that and acquire a diamond in the rough. In the right hands, with a deep pocketed suitor, this company can soar and its technology become mainstream.
Big companies are snapping up small companies right and left with the stock market at an all time high. They could buy BSD with a combination of cash and shares and it would cost them very little. Medtronic bought Covidien for $43B. Boston Scientific and Stryker have no microwave thermal ablation equipment. BSD could be had for a song. Think about it.